Vtv Therapeutics Inc., of High Point, N.C., said data from research on its small-molecule GLP-1R agonist were presented during the Keystone Symposium, being held this week in Keystone, Colo. "TTP273: Oral, G-protein Pathway Selective, Clinical-Stage GLP-1 Receptor (GLP-1R) Agonist" demonstrated that TTP273, an allosteric standalone agonist, indicated "functional selectivity" for a subset of the full GPCR signaling repertoire.